Thrombophilia as a risk factor of central retinal vein occlusion;Trombofilia jako czynnik ryzyka zakrzepicy żyły środkowej siatkówki

Klinika Oczna

Volumn 105, Issue 3-4, 2003, Pages 221-224

  Undas, Anetta ^a   Kubicka Trza̧ska, Agnieszka ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiphospholipid antibodies; Central retinal vein occlusion; Homocysteine; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; LIPOPROTEIN A; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1;

BLOOD; DIABETES MELLITUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; THROMBOPHILIA;

ANTIBODIES, ANTIPHOSPHOLIPID; DIABETES COMPLICATIONS; FACTOR V; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN(A); PLASMINOGEN ACTIVATOR INHIBITOR 1; RETINAL VEIN OCCLUSION; RISK FACTORS; THROMBOPHILIA;

EID: 2442536280     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Albissini R., Coppola A., Loffredo M. et al.: Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost, 1998, 80, 702-703.
2. Bandello F., Vigano D'Angelo S., Parlavecchia M. et al.: Hypercoagulability and high lipoprotein (a) levels in patients with central retinal vein occlusion. Thromb. Haemost., 1994, 72, 39-43.
3. Boyd S., Owens D., Gin T. et al.: Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and vWF on central retinal vein occlusion. Br. J. Ophthalmol., 2001, 85, 1313-1319.
4. Cervera R., Piette J. C., Font J. et al.: Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum, 2002, 46, 1019-1027.
5. Fegan C. D.: Central retinal vein occlusion and thrombophilia. Eye, 2002, 16, 98-106.
6. Glacet-Bernard A., Bayani N., Chretien P. et al.: Antiphospholipid antibodies in retinal vascular occlusions. Arch. Ophthalmol., 1994, 112, 790-795.
7. Glueck C. J., Bell H., Vadlamani L. et al.: Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch. Ophthalmol., 1999, 117, 43-49.
8. Gottlieb J. L., Blice J. P., Mestichelli B. et al.: Activated protein C resistance, factor V Leiden and central retinal vein occlusion in young adults. Arch. Ophthalmol., 1998, 116, 577-579.
9. Greiner K., Peetz D., Winkgen A. et al.: Genetic thrombophilia in patients with retinal vascular occlusion. Int. Ophthalmol., 1999, 23, 155-160.
10. Gutman F. A.: Evaluation of a patient with central retinal vein occlusion. Ophthalmology, 1983, 90, 481-483.
11. Lahey J. M., Tunc M., Kearney J. et al.: Laboratory evaluation of hypercoagulable states in patients with retinal vein occlusion who are less than 56 years of age. Ophthalmology, 2002, 109, 126-131.
12. Larsson J., Hillarp A., Olafsdottir E., Bauer B.: Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol. Scand., 1999, 77, 634-637.
13. Marcucci R., Bertini L., Giusti B. et al.: Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb. Haemost, 2001, 86, 772-776.
14. Thomas R. T.: Hypercoagulability syndromes. Arch. Intern. Med., 2001, 161, 2433-2439.
15. Vine A. K.: Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am. J. Ophthalmol., 2001, 129, 640-644.
16. Weger M., Stanger O., Deutschmann H. et al.: Hyperhomocyst (e) nemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion. Ophthalmology, 2002, 109, 1105-1109.
17. Williamson T. H., Rumley A., Lowe G. D. O.: Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br. J. Ophthalmol., 1996, 80, 203-208.